ClinicalTrials.gg
CompletedNCT02409459Updated Feb 20, 2018Results posted

Blinded Randomized Placebo-Controlled Study Efficacy and Safety of Injectafer in ID Patients With Fibromyalgia

A Phase 2 interventional study of Injectafer and Placebo in Iron Deficiency and Fibromyalgia, sponsored by American Regent, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-02-20.

Sponsored by American Regent, Inc. (part of Daiichi Sankyo) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
81
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 40 studies testing ferric carboxymaltose in Iron Deficiencies — 8 open to participants now, 8 under way, 2 of them phase 3. ferric carboxymaltose · Iron Deficiencies.

Enrollment
26th of 40
81 · median 134
Started
2015
with 1 other
Phase 2
2 of 40
none open now
Registered
20th of 40
by date
Lead sponsor
1 of 40
American Regent, Inc.

Among the 40 studies testing ferric carboxymaltose in Iron Deficiencies, this one is the 26th largest by enrollment, is one of 2 that started in 2015, is one of 2 in phase 2, and was the 20th registered.

Iron Deficiencies

386 studies on the registry are indexed under Iron Deficiencies; 80 are open to participants now.

Browse Iron Deficiencies studies →

Open to participants now

8 of the 40 studies testing ferric carboxymaltose in Iron Deficiencies are open now, in 7 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About ferric carboxymaltose

ferric carboxymaltose: first FDA approval 2013 (INJECTAFER). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 55 Iron Deficiencies studies recruiting now, 23 (42%) set no upper age limit and 28 (51%) stop at 75 or younger; 15 take children under 18; 16 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 40 studies testing ferric carboxymaltose in Iron Deficiencies, or all of them as a file.
02

Study summary

This study investigates the efficacy and safety of an IV iron Injectafer in the treatment of iron deficient patients with fibromyalgia. Eligible subjects will be randomized in a 1:1 ratio to receive Injectafer or Placebo on days 0 and 5. All treated subjects will be followed for efficacy and safety for 42 days.

Read the detailed description

This is a blinded, randomized, placebo-controlled study. All subjects who meet the inclusion requirements and no exclusion criteria will be entered into an up to 14 day screening phase. Eligible subjects will be randomized in a 1:1 ratio to receive Injectafer or Placebo on days 0 and 5. All treated subjects will be followed for efficacy and safety for 42 days. Subjects will visit the clinic on days 0 and 5 for treatment, and then on days 14, 28, and 42. The subject's participation in the study will be for approximately 42 days from day 0.

03

Conditions studied

  • Iron Deficiency
  • Fibromyalgia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female subject's ≥ 18 years of age, able to give to the study.
  • Fibromyalgia diagnosis based on The 2011 modification of the American College of Rheumatology (ACR) 's 2010 preliminary criteria for diagnosing fibromyalgia (2011ModCr)
  • A baseline score ≥ 60 on the FIQR
  • Subject's current medications to treat fibromyalgia, including pain medicines, anti-depressants, sleep medications must be on a stable dose for at least 30 days.
  • Subject's current narcotic medication must be on a stable dose for at least 30 days prior to randomization
  • Subjects at risk for pregnancy must have a negative pregnancy test at baseline and be practicing an acceptable form of : have had a hysterectomy or tubal ligation, or otherwise be incapable of pregnancy, or have practiced any of the following methods of contraception for at least one month prior to study entry: hormonal contraceptives, spermicide and barrier, intrauterine device, partner sterility.

Exclusion criteria

Exclusion Criteria:

  • Parenteral iron use within 4 weeks prior to screening.
  • History of > 10 blood transfusions in the past 2 years.
  • Anticipated need for blood transfusion during the study.
  • Known reaction to any component of Injectafer® (Ferric Carboxymaltose).
  • Current or acute or chronic infection other than viral upper respiratory tract infection
  • (other than basal or squamous cell skin cancer or the subject has been cancer free for ≥ 5 years).
  • Active inflammatory arthritis (e.g. rheumatoid arthritis, SLE).
  • Pregnant or lactating women.
  • Severe peripheral vascular disease with significant skin changes.
  • Seizure disorder currently being treated with medication.
  • Baseline ferritin ≥ 50 ng/mL.
  • Baseline TSAT ≥ 20%.
  • History of hemochromatosis or hemosiderosis or other iron storage disorders.
  • Known positive hepatitis with evidence of active disease.
  • greater than the .
  • Calcium or phosphorous outside the normal range.
  • Known positive antigen (HBsAg) or viral antibody (HCV) with evidence of active hepatitis (i.e., /ALT greater than the upper limit of normal).
  • Known positive -1/HIV-2 antibodies (anti-HIV)
  • Received an drug within 30 days before randomization.
  • Chronic alcohol or drug abuse within the past 6 months.
  • Any other pre-existing laboratory abnormality, medical condition or disease which in view of the investigator participation in this study may put the subject at risk.
  • Subject unable to comply with the study requirements.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
81 participants (actual)

Study arms

  • Experimental
    Injectafer

    15 mg/kg up to 750 mg undiluted blinded dose of IV Injectafer (ferric carboxymaltose) at 100 mg/minute

    Drug: Injectafer

  • Placebo comparator
    Placebo

    15 cc of Normal Saline IV push at 2 ml/minute

    Drug: Placebo

Interventions

  • Also known as: Ferric Carboxymaltose (FCM)

  • DrugPlacebo

    Normal saline solution

    Also known as: Saline solution

06

What researchers measure

Primary outcomes

  1. Proportion of Patients With a ≥13 Point Improvement in FIQR Score

    The primary efficacy endpoint was the percentage of subjects who had a ≥13-point improvement in the FIQR from baseline to Day 42.

    Time frame: Day 42

Secondary outcomes

  1. Change in BPI, Pain Interference

    The short version of the Brief Pain Inventory (BPI) includes front and back body diagrams, 4 pain severity items and 7 pain interference items rated on 0-10 scales (with 0 being the best outcome and 10 being the worst outcome), and a question about percentage of pain relief by analgesics. The Pain Interference Score is calculated by adding the scores for the 7 pain interference questions and then dividing by 7 to give a score out of 10.

    Time frame: Change from Baseline in Brief Pain Inventory Pain Interference Score at Day 42

  2. Change in FIQR Score

    The FIQR has 21 individual questions. All questions are based on an 11-point numeric rating scale of 0 to 10, with 10 being 'worst' and all questions are framed in the context of the past 7 days. The summed score for function (range 0 to 90) is divided by 3, the summed score for overall impact (range 0 to 20) is not changed, and the summed score for symptoms (range 0 to 100) is divided by 2. The total FIQR is the sum of the three modified domain scores.

    Time frame: Change from Baseline in FIQR score at Day 42

  3. Change in BPI, Pain Severity

    The short version of the Brief Pain Inventory (BPI) includes front and back body diagrams, 4 pain severity items and 7 pain interference items rated on 0-10 scales (with 0 being the best outcome and 10 being the worst outcome), and a question about percentage of pain relief by analgesics. The Pain Severity Score is calculated by adding the scores for the 4 pain severity questions and then dividing by 4 to give a severity score out of 10.

    Time frame: Change from Baseline in Brief Pain Inventory Pain Severity Score at Day 42

  4. Change in Fatigue Visual Numeric Scale

    Scores range from 0 to 10, with the higher score indicating more fatigue.

    Time frame: Change from Baseline in Fatigue Visual Numeric Scale at Day 42

  5. Change in Iron Indices, Serum Ferritin

    Time frame: Change from Baseline in Iron Indices, Serum ferritin at Day 42

  6. Change in Iron Indices - Transferrin Saturation

    Time frame: Change from baseline in Iron Indices, Transferrin saturation, at Day 42

07

Results

Posted Dec 13, 2017

Participant flow

Participant flow — Overall Study
MilestoneInjectaferPlacebo
Started4140
Completed4039
Not completed11

Outcome measures

PrimaryProportion of Patients With a ≥13 Point Improvement in FIQR Score

The primary efficacy endpoint was the percentage of subjects who had a ≥13-point improvement in the FIQR from baseline to Day 42.

Time frame:
Day 42
Reported as:
Count of participants · Participants
Proportion of Patients With a ≥13 Point Improvement in FIQR Score
ParticipantsInjectaferPlacebo
Proportion of Patients With a ≥13 Point Improvement in FIQR Score3026
SecondaryChange in BPI, Pain Interference

The short version of the Brief Pain Inventory (BPI) includes front and back body diagrams, 4 pain severity items and 7 pain interference items rated on 0-10 scales (with 0 being the best outcome and 10 being the worst outcome), and a question about percentage of pain relief by analgesics. The Pain Interference Score is calculated by adding the scores for the 7 pain interference questions and then dividing by 7 to give a score out of 10.

Time frame:
Change from Baseline in Brief Pain Inventory Pain Interference Score at Day 42
Reported as:
Mean · units on a scale
Change in BPI, Pain Interference
units on a scaleInjectaferPlacebo
Change in BPI, Pain Interference-4.1 ± 3.3-2.3 ± 2.6
SecondaryChange in FIQR Score

The FIQR has 21 individual questions. All questions are based on an 11-point numeric rating scale of 0 to 10, with 10 being 'worst' and all questions are framed in the context of the past 7 days. The summed score for function (range 0 to 90) is divided by 3, the summed score for overall impact (range 0 to 20) is not changed, and the summed score for symptoms (range 0 to 100) is divided by 2. The total FIQR is the sum of the three modified domain scores.

Time frame:
Change from Baseline in FIQR score at Day 42
Reported as:
Mean · units on a scale
Change in FIQR Score
units on a scaleInjectaferPlacebo
Change in FIQR Score-45.0 ± 29.5-29.7 ± 27.0
SecondaryChange in BPI, Pain Severity

The short version of the Brief Pain Inventory (BPI) includes front and back body diagrams, 4 pain severity items and 7 pain interference items rated on 0-10 scales (with 0 being the best outcome and 10 being the worst outcome), and a question about percentage of pain relief by analgesics. The Pain Severity Score is calculated by adding the scores for the 4 pain severity questions and then dividing by 4 to give a severity score out of 10.

Time frame:
Change from Baseline in Brief Pain Inventory Pain Severity Score at Day 42
Reported as:
Mean · units on a scale
Change in BPI, Pain Severity
units on a scaleInjectaferPlacebo
Change in BPI, Pain Severity-3.1 ± 2.7-1.8 ± 2.1
SecondaryChange in Fatigue Visual Numeric Scale

Scores range from 0 to 10, with the higher score indicating more fatigue.

Time frame:
Change from Baseline in Fatigue Visual Numeric Scale at Day 42
Reported as:
Mean · units on a scale
Change in Fatigue Visual Numeric Scale
units on a scaleInjectaferPlacebo
Change in Fatigue Visual Numeric Scale-3.7 ± 3.2-1.7 ± 2.2
SecondaryChange in Iron Indices, Serum Ferritin
Time frame:
Change from Baseline in Iron Indices, Serum ferritin at Day 42
Reported as:
Mean · ug/L
Change in Iron Indices, Serum Ferritin
ug/LInjectaferPlacebo
Change in Iron Indices, Serum Ferritin292.5 ± 145.92.0 ± 13.8
SecondaryChange in Iron Indices - Transferrin Saturation
Time frame:
Change from baseline in Iron Indices, Transferrin saturation, at Day 42
Reported as:
Mean · percent of transferrin saturation
Change in Iron Indices - Transferrin Saturation
percent of transferrin saturationInjectaferPlacebo
Change in Iron Indices - Transferrin Saturation24.4 ± 11.45.8 ± 15.1

Adverse events

Collected over 7 months. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Injectafer0/41 (0%)0/41 (0%)16/41 (39%)
Placebo0/40 (0%)0/40 (0%)2/40 (5%)
Most frequent other events
Most frequent other events
EventInjectaferPlacebo
FlushingVascular disorders6/410/40
NauseaGastrointestinal disorders3/410/40
DizzinessNervous system disorders2/410/40
Oral herpesInfections and infestations0/411/40
DehydrationMetabolism and nutrition disorders0/411/40
DermatitisSkin and subcutaneous tissue disorders1/410/40
Ear discomfortEar and labyrinth disorders1/410/40
DysgeusiaNervous system disorders1/410/40
HeadacheNervous system disorders1/410/40
ParaesthesiaNervous system disorders1/410/40

Baseline characteristics

Age, Continuous
Age, Continuous(years)PlaceboInjectaferTotal
Mean44 ± 10.8541 ± 11.0743 ± 10.97
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboInjectaferTotal
Female404080
Male011
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PlaceboInjectaferTotal
Race — African American7714
Race — Asian011
Race — Caucasian303363
Race — Hispanic202
Race — Other101
History of iron intolerance
History of iron intolerance(Participants)PlaceboInjectaferTotal
No373572
Yes369
History of drug allergy
History of drug allergy(Participants)PlaceboInjectaferTotal
No172138
Yes232043
IRLS score per Arm/Group
IRLS score per Arm/Group(units on a scale)PlaceboInjectaferTotal
Mean16.3 ± 14.913.4 ± 13.1614.8 ± 14.04
08

Study locations

1 site
  • Clinical Research Solutions
    Franklin, Tennessee 37064, United States
09

References and documents

Publications

  • Boomershine CS, Koch TA, Morris D. A Blinded, Randomized, Placebo-Controlled Study to Investigate the Efficacy and Safety of Ferric Carboxymaltose in Iron-Deficient Patients with Fibromyalgia. Rheumatol Ther. 2018 Jun;5(1):271-281. doi: 10.1007/s40744-017-0088-9. Epub 2017 Nov 17. PubMed 29149437 ↗

Individual participant data

Plan to share: Yes

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2015, a primary completion of Oct 2015 and a completion of Mar 2016. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2017, 2 years 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 1, 2015
First posted
Apr 6, 2015
Start
Mar 2015
Primary completionActual
Oct 2015
CompletionActual
Mar 2016
Results first posted
Dec 13, 2017
Last update
Feb 20, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 20, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02409459
Responsible party
Sponsor
First posted
Apr 6, 2015
Start date
Mar 2015
Primary completion
Oct 2015
Completion
Mar 2016
Results posted
Dec 13, 2017
Last update
Feb 20, 2018

Study contacts

Mark A Falone, MD
study director · American Regent, Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ferric carboxymaltose

Start the discussion